Hutchison China Meditech Limited Vesting of awards under Long Term Incentive Plan (1657J)
28 Mars 2018 - 8:01AM
UK Regulatory
TIDMHCM
RNS Number : 1657J
Hutchison China Meditech Limited
28 March 2018
Vesting of awards under the Long Term Incentive Plan
London: Wednesday, March 28, 2018: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that following the
publication of the 2017 annual report of Chi-Med on March 26, 2018,
the following awards granted under the Long Term Incentive Plan
("LTIP") on March 15, 2017 to Mr Christian Hogg, Mr Johnny Cheng
and Dr Weiguo Su were vested on March 27, 2018:-
Award Holders Number of American
depositary shares
("ADS")
Person Discharging Managerial
Responsibilities
Mr Christian Hogg (Executive Director
and Chief Executive Officer) 4,470
Mr Johnny Cheng (Executive Director
and Chief Financial Officer) 1,378
Dr Weiguo Su (Executive Director
and Chief Scientific Officer) 1,632
Total 7,480
===================
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation.
(a) Mr Christian Hogg
1 Details of the person discharging managerial responsibilities/person closely associated
----- ---------------------------------------------------------------------------------------------------------------
a) Name Mr Christian Hogg
----- ------------------------------------------------------- ------------------------------------------------------
2 Reason for the notification
----- ---------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Executive Officer
----- ------------------------------------------------------- ------------------------------------------------------
b) Initial notification/Amendment Initial notification
----- ------------------------------------------------------- ------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----- ---------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
----- ------------------------------------------------------- ------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
----- ------------------------------------------------------- ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----- ---------------------------------------------------------------------------------------------------------------
Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
a) instrument of US$1.00
Identification code ADS ISIN: US44842L1035
----- ------------------------------------------------------- ------------------------------------------------------
b) Nature of the transaction Vesting of awards granted on March 15, 2017 under
Chi-Med's LTIP
----- ------------------------------------------------------- ------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
Nil 4,470 ADS
--------- ----------
----- ------------------------------------------------------- ------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
----- ------------------------------------------------------- ------------------------------------------------------
e) Date of the transaction 2018-03-27
----- ------------------------------------------------------- ------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
----- ------------------------------------------------------- ------------------------------------------------------
(b) Mr Johnny Cheng
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Mr Johnny Cheng
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Financial Officer
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Vesting of awards granted on March 15, 2017 under Chi
Med's LTIP
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
Nil 1,378 ADS
--------- ----------
---- -------------------------- ------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- -------------------------- ------------------------
e) Date of the transaction 2018-03-27
---- -------------------------- ------------------------
f) Place of the transaction Nasdaq Stock Market
---- -------------------------- ------------------------
(c) Dr Weiguo Su
1 Details of the person discharging managerial responsibilities/person closely associated
---- ----------------------------------------------------------------------------------------------------------------
a) Name Dr Weiguo Su
---- ------------------------------------------------------- -------------------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Scientific Officer
---- ------------------------------------------------------- -------------------------------------------------------
b) Initial notification/Amendment Initial notification
---- ------------------------------------------------------- -------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
---- ----------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
---- ------------------------------------------------------- -------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
---- ------------------------------------------------------- -------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
---- ------------------------------------------------------- -------------------------------------------------------
b) Nature of the transaction Vesting of awards granted on March 15, 2017 under
Chi-Med's LTIP
---- ------------------------------------------------------- -------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
Nil 1,632 ADS
--------- ----------
---- ------------------------------------------------------- -------------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
---- -------------------------- ---------------------
e) Date of the transaction 2018-03-27
---- -------------------------- ---------------------
f) Place of the transaction Nasdaq Stock Market
---- -------------------------- ---------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance
& Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUQGWUPRUAR
(END) Dow Jones Newswires
March 28, 2018 02:01 ET (06:01 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
